FDA Approval for VORICONAZOLE issued to MYLAN PHARMS INC
The FDA has approved a labeling supplement (SUPPL-20) for Mylan's generic voriconazole tablets (ANDA 090547) on November 16, 2026. This approval is reported by Quantisnow, a platform that tracks FDA regulatory updates. The article also provides historical stock performance context for Viatris Inc. (VTRS), Mylan's parent company, after similar headlines.
Key facts: Viatris Closes Pacira Deal; 9-Month Growth; Target Raised
Viatris (VTRS) completed its acquisition of Pacira BioSciences on November 17, 2026, gaining full ownership of Pacira, whose Nasdaq shares will be delisted. The company also reported revenue growth of 2%, adjusted EBITDA increase of 6%, and EPS growth of 8% for the first nine months of 2026, driven by complex generics and China. Leerink Partners maintained an Outperform rating on Viatris and raised its price target to $24 from $22.
Viatris Completes Acquisition of Pacira BioSciences for $36.50 Per Share, Expanding Non-Opioid Pain Management Portfolio
Viatris Inc. (Nasdaq: VTRS) has completed its acquisition of Pacira BioSciences Inc. (Nasdaq: PCRX) for $36.50 per share, significantly expanding its U.S. innovative medicines business and strengthening its position in the non-opioid pain management market. This strategic move, initially announced in October 2026, is expected to contribute between $90 million and $100 million in revenue for Viatris during the remainder of 2026. The acquisition integrates Pacira's specialized portfolio and commercial capabilities, enhancing Viatris's growth strategy in key therapeutic areas.
After battle with activist investor, Pacira BioSciences finds $1.7 billion deal gain from pain
Viatris has completed its $1.7 billion acquisition of Pacira BioSciences, a pain drug company. This deal comes after Pacira BioSciences had a battle with an activist investor. Former New Jersey governor Chris Christie had served as one of the company's directors for seven years.
Merger converts 32,675 director options into a cash right at Pacira BioSciences (PCRX).
Pacira BioSciences director Thomas G. Wiggans disposed of 32,675 stock options on November 17, 2026, the effective date of a merger with Viatris Inc. These options were canceled and converted into a cash right based on the $36.50 per-share offer price minus the $23.42 per-share exercise price, subject to tax withholding. After this transaction, Wiggans reported zero remaining options.
Viatris closes $1.65 billion Pacira buy, adding $90 million to $100 million of 2026 sales
Viatris completed its $1.65 billion all-cash acquisition of Pacira BioSciences on November 17, 2026, purchasing shares at $36.50 each. The deal, which adds two patent-protected pain management drugs to Viatris's portfolio, is expected to contribute $90 million to $100 million in revenue by year-end 2026. This acquisition represents a strategic move for Viatris into branded pain drugs, complementing its own non-opioid pain candidate, fast-acting meloxicam, awaiting an FDA decision.
VTRS: Viatris Inc. filed SEC Form 8-K: Completion of Acquisition or...
Viatris Inc. (VTRS) has completed its cash acquisition of Pacira BioSciences for $36.50 per share, with approximately 66.46% of shares tendered. The acquisition is expected to add $90 million to $100 million in revenue for Viatris for the remainder of 2026, strengthening its U.S. innovative medicines business and providing a position in non-opioid pain management. Untendered shares were converted in a merger, making Pacira a wholly owned subsidiary of Viatris.
Form 8K Viatris Inc For: 17 November By Investing.com
Viatris Inc. filed a Form 8K on November 17, 2026, as reported by Investing.com. The article briefly mentions the filing without detailing its contents, and includes the stock symbol VTRS which showed a slight decrease.
Pacira BioSciences Announced Transfer or Voluntary Withdrawal of Listing
Pacira BioSciences (PCRX) announced its intention to delist its shares and deregister them under Section 12(b) following the completion of its merger with Viatris. The company also plans to file Form 15 to terminate registration under Section 12(g) and suspend its Exchange Act reporting obligations. This decision was made on November 17, 2026, and a request for a trading halt has been sent to Nasdaq.
Without a stockholder vote, Pacira BioSciences (PCRX) completes its cash merger with Viatris.
Pacira BioSciences (PCRX) has completed its merger with Viatris, after Viatris subsidiary Purchaser acquired 66.46% of Pacira's outstanding shares through a cash tender offer of $36.50 per share. The merger closed on November 17, 2026, without a Pacira stockholder vote, utilizing Section 251(h) of the DGCL. Pacira will now operate as a wholly-owned subsidiary of Viatris, and its shares will be delisted from the Nasdaq Global Select Market.
VTRS: Viatris tender offer for Pacira closes with 66.46% tendered
Viatris's subsidiary, Peach Purchaser Sub, has completed its $36.50 per share cash tender offer for Pacira BioSciences, with approximately 66.46% of Pacira shares tendered. The merger is set to close on November 17, 2026, leading to Pacira's delisting from Nasdaq. Shareholders who tendered or did not tender will receive $36.50 per share in cash, but those who did not tender will lose their ownership of Pacira shares.
About 66.46% tendered, Pacira BioSciences (PCRX) is set to merge without a stockholder vote.
Viatris subsidiary Peach Purchaser Sub's tender offer for Pacira BioSciences (PCRX) at $36.50 per share has successfully concluded. Approximately 66.46% of outstanding shares were validly tendered, meeting the minimum condition for the merger. As a result, Peach Purchaser Sub will merge into Pacira BioSciences on November 17, 2026, without requiring a stockholder vote, after which Pacira shares will be delisted from Nasdaq.
United Natural Foods To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
This article compiles ten recent analyst rating changes and price target adjustments for various companies, including upgrades, downgrades, and maintained ratings. Notably, Goldman Sachs upgraded United Natural Foods (NYSE:UNFI) from Neutral to Buy, raising its price target to $60 from $49, indicating a potential rally of around 24%. Other companies covered include CG Oncology, Viatris, Rubrik, Allarity Therapeutics, IDACORP, Tyson Foods, Range Resources, GXO Logistics, and Red Cat Holdings.
Pacira BioSciences (PCRX) complied with Nasdaq’s voluntary withdrawal rules.
Pacira BioSciences, Inc. (PCRX) has filed a Form 25 with Nasdaq for the voluntary withdrawal of its common stock from listing and registration. Nasdaq has certified that Pacira complied with the necessary rules and requirements for this voluntary withdrawal. This action signifies the company's delisting from the Nasdaq Stock Market.
Leerink Partners maintains Viatris at Outperform, raises price target to $24 from $22
Leerink Partners has reiterated its "Outperform" rating for Viatris and increased its price target from $22 to $24, an approximate 9.1% rise. This new price target suggests a 15.7% upside from Viatris's closing price of $20.74 on November 16. Other recent analyst actions on Viatris include a "Overweight" rating from Barclays with a $25 target and "Neutral" ratings from JP Morgan and Piper Sandler with targets of $21 and $14, respectively.
Viatris Completes Acquisition of Pacira BioSciences
Viatris has finalized its acquisition of Pacira BioSciences, a non-opioid pain management company, at a cash price of $36.50 per share. Pacira's shares will be delisted from Nasdaq, and the acquisition is expected to add $90 million to $100 million in revenue for Viatris for the remainder of 2026. This move aims to establish Viatris as a leader in non-opioid pain management.
FDA Approval for GLATIRAMER ACETATE issued to MYLAN
The FDA has approved a labeling update for Mylan's generic glatiramer acetate 20mg/mL injection (ANDA 091646). This supplement (SUPPL-24) was approved on November 9, 2026, and pertains only to changes in the package insert and medication guide, not a new product launch. The original approval for this generic product was on October 3, 2017.
T. Rowe Price reports a Viatris (VTRS) stake with sole voting power over 56.7 million shares.
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G/A, reporting beneficial ownership of 58,912,075 shares, or 5.1%, of Viatris Inc. (VTRS) common stock as of September 30, 2026. The filing indicates that T. Rowe Price holds sole voting power over 56,678,388 shares and sole dispositive power over all 58,912,075 beneficially owned shares, while explicitly denying beneficial ownership. This disclosure provides insight into the institutional ownership structure of Viatris.
A $1.65 Billion Buyout Deal Puts a Spotlight on PolyPid Ahead of Its FDA Decision (NASDAQ: PYPD)
PolyPid (NASDAQ: PYPD) is gaining attention due to recent multi-billion dollar buyouts in the prolonged drug delivery and hospital medicines sector, ahead of its November 28 FDA goal date for D-PLEX₁₀₀. The company's lead candidate, D-PLEX₁₀₀, aims to prevent surgical-site infections through sustained local delivery, supported by positive Phase 3 results and a commercial partnership with Azurity Pharmaceuticals. This potential FDA approval could transition PolyPid into a revenue-generating company, mirroring the successful business models of acquired firms like Pacira BioSciences and Heron Therapeutics.
CADILLAC FORMULA 1® TEAM WELCOMES VIATRIS AS OFFICIAL GLOBAL PHARMACEUTICAL PARTNER
The Cadillac Formula 1® Team announced a multiyear partnership with Viatris Inc., making Viatris the team's Official Global Pharmaceutical Partner starting in 2027. This collaboration unites two American entities with global ambitions, highlighting shared values of precision, reliability, and performance in both motorsport and medicine. The partnership aims to showcase Viatris to new audiences as the Cadillac F1 Team establishes itself on the global stage.
CADILLAC FORMULA 1® TEAM WELCOMES VIATRIS AS OFFICIAL GLOBAL PHARMACEUTICAL PARTNER
The Cadillac Formula 1® Team announced a multiyear partnership with Viatris Inc., making the global healthcare company its Official Global Pharmaceutical Partner starting in 2027. This collaboration brings together two American companies focused on precision, reliability, and performance. The partnership aims to showcase a shared spirit of ambition and ingenuity to new global audiences as both organizations pursue their respective evolutions.
Viavi Solutions (NASDAQ:VIAV) EVP Sells 13,806 Shares of Company Stock
Viavi Solutions (NASDAQ:VIAV) EVP Paul McNab sold 13,806 shares of company stock on November 12th, 2026, for a total of $443,448.72, reducing his holdings by 23.07%. This transaction follows a previous sale in September and comes as Viavi reported strong quarterly earnings, beating consensus estimates for both EPS and revenue, though the stock recently traded down to $30.78. Analysts maintain a "Moderate Buy" rating with a consensus price target of $57.83.
Viatris subsidiary offers $36.50 for each Pacira BioSciences (PCRX) share.
Viatris Inc.'s wholly-owned subsidiary, Peach Purchaser Sub Inc., has launched a tender offer to acquire all outstanding shares of Pacira BioSciences (PCRX) for $36.50 per share in cash. This amendment to the tender offer statement primarily updates the litigation disclosure, noting that two Pacira stockholders have filed complaints in New York state court seeking to block the merger or obtain damages due to allegedly omitted merger disclosures. Pacira and Viatris intend to vigorously defend against these actions, believing their disclosures comply with applicable law.
Ingram Micro Holding Corp. (INGM) to Join S&P SmallCap 600 November 17
Ingram Micro Holding Corp. (INGM) is set to join the S&P SmallCap 600 index, replacing Pacira BioSciences, before trading opens on November 17, 2026. This change is due to Pacira being acquired by Viatris. The index inclusion could lead to adjustments in holdings by index-tracking funds, making trading around the effective date a key development to monitor.
Did Raised Guidance Just Shift Viatris (VTRS) Investment Narrative?
Viatris (VTRS) reported Q3 2026 revenue of US$3,749.5 million and a net loss of US$325.3 million. Despite the loss, the company raised its full-year 2026 revenue guidance and maintained its quarterly dividend, signaling a focus on earnings quality, cash discipline, and shareholder returns. The article explores how this guidance shift impacts Viatris's investment narrative, considering ongoing operational challenges like product recalls and facility remediation alongside the strategy to move towards higher-value products.
Viatris Inc. stock falls Thursday, underperforms market
Viatris Inc. (VTRS) shares fell 1.85% on Thursday, closing at $20.67. This decline occurred during a broader market downturn, with both the S&P 500 Index and Dow Jones Industrial Average also experiencing losses. The stock's drop ended a four-day winning streak for Viatris.
MediWound's Penny EPS Beat Is Overshadowed By A 53% Revenue Miss And A Retreat From Its 2026 Revenue Outlook
MediWound technically beat EPS estimates but missed revenue consensus by 53.2% and retracted its 2026 revenue outlook due to unpredictable U.S. government funding. While the company saw improvements in gross margin, NexoBrid demand, and government contracts, its near-term financial stability is compromised, and the balance sheet required fresh equity. Investors are now focused on the mid-2027 VALUE clinical trial readout and capacity expansion rather than immediate revenue figures.
Viatris Named to Fortune's World's Best Workplaces™ List for Second Consecutive Year
Viatris (Nasdaq: VTRS) has been recognized on Fortune's World's Best Workplaces list for the second consecutive year, reflecting its commitment to fostering a valued and supportive environment for its employees. The recognition is based on confidential employee feedback gathered through Great Place To Work's rigorous assessment process, which included over 9 million survey responses globally. This achievement highlights Viatris's dedication to its colleagues and its positive workplace culture.
Viatris Named to Fortune's World's Best Workplaces™ List for Second Consecutive Year
Viatris Inc. has been recognized on Fortune's World's Best Workplaces™ list for the second consecutive year, based on confidential employee feedback gathered by Great Place To Work. This honor highlights Viatris's commitment to fostering a valued and supportive workplace culture where colleagues feel empowered to make an impact. The company's Chief People and Corporate Affairs Officer, Lara Ramsburg, emphasized that this recognition reflects the collective contributions and sense of purpose shared by Viatris colleagues worldwide.
A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
Five biotech companies—BridgeBio, Vertex, Gilead, Viatris, and Praxis—have FDA target action dates between November 27 and December 27, 2026. These PDUFA dates mark when pending applications could be decided, with Vertex's povetacicept for IgA nephropathy on November 30 being a key highlight. The report also details Q3 revenues and 2026 guidance for several companies, noting positive updates for Vertex, Gilead, and Viatris, alongside flat Q3 revenues for Viatris.
A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
The final weeks of 2026 are marked by a cluster of U.S. Food and Drug Administration (FDA) target action dates for several drugmakers. Five companies, including BridgeBio Pharma, Vertex Pharmaceuticals, Gilead Sciences, Viatris Inc., and Praxis Precision Medicines, have Prescription Drug User Fee Act (PDUFA) dates between November 27 and December 27, 2026, covering a range of applications for conditions such as muscular dystrophy, IgA nephropathy, multiple myeloma, acute pain, and epileptic encephalopathies. These dates are crucial milestones for the companies and their investigational drugs, though they do not guarantee FDA approval.
Ingram Micro to join S&P SmallCap 600, replacing Pacira BioSciences
Ingram Micro Holding (INGM) is set to join the S&P SmallCap 600, replacing Pacira BioSciences (PCRX), effective before market open on November 17, 2026. This change is due to Pacira BioSciences being acquired by Viatris (VTRS). Following the announcement, Ingram Micro's stock price increased by approximately 3% in pre-market trading.
Ingram Micro jumps after securing spot in S&P SmallCap 600
Ingram Micro Holding Ltd (NYSE:INGM) shares rose after S&P Dow Jones Indices announced the technology distributor would join the S&P SmallCap 600. This inclusion, which will replace Pacira Pharmaceuticals Inc (NASDAQ:PCRX), is expected to provide near-term technical support. The news follows a strong third-quarter earnings beat and upbeat full-year guidance from Ingram Micro.
23 Mid Cap Stocks Hit 52-Week Highs On Wednesday
On Wednesday, November 11, 23 Mid Cap US and Canada-listed stocks within the Trefis coverage universe reached 52-week highs. Mid Cap is defined as a market value between $10 billion and $40 billion, with Cboe Global Markets (CBOE) being the largest at $38.6 billion. The Financials sector accounted for 8 of these 23 companies, while the S&P 500 was down 2.3% over the past month.
Ingram Micro set to join S&P SmallCap 600 following Viatris-Pacira deal
Ingram Micro (INGM) is scheduled to replace Pacira BioSciences (PCRX) in the S&P SmallCap 600 before market open on November 17. This change follows Viatris' (VTRS) anticipated acquisition of Pacira. INGM shares saw approximately a 4% increase in extended trading after the announcement.
A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
The biotech industry is facing a busy end to 2026, with several U.S. FDA target action dates scheduled from late November to late December. Five companies—BridgeBio Pharma, Vertex Pharmaceuticals, Gilead Sciences, Viatris Inc., and Praxis Precision Medicines—have Prescription Drug User Fee Act (PDUFA) dates for various drug applications covering conditions like muscular dystrophy, IgA nephropathy, multiple myeloma, acute pain, and epileptic encephalopathies. These dates are crucial for the companies as they await regulatory decisions that could significantly impact their product pipelines and market performance.
Ingram Micro Holding Set to Join S&P SmallCap 600
Ingram Micro Holding (INGM) is scheduled to join the S&P SmallCap 600 index on November 17, 2026. This move will replace Pacira BioSciences (PCRX), which is being acquired by S&P 500 constituent Viatris (VTRS). The change is expected to drive index-tracking fund demand for Ingram Micro's shares.
Ingram Micro Holding Set to Join S&P SmallCap 600
Ingram Micro Holding (INGM) will be added to the S&P SmallCap 600 index on November 17, 2026, replacing Pacira BioSciences (PCRX). Pacira BioSciences is being removed due to its pending acquisition by Viatris (VTRS), an S&P 500 constituent. This change is expected to bring index-tracking fund demand for Ingram Micro Holding's shares.
Ingram Micro Holding Set to Join S&P SmallCap 600
Ingram Micro Holding Corp. (NYSE: INGM) will replace Pacira BioSciences Inc. (NASD: PCRX) in the S&P SmallCap 600, effective prior to the opening of trading on Tuesday, November 17, 2026. This change is due to Viatris Inc. (NASD: VTRS) acquiring Pacira BioSciences. S&P Dow Jones Indices announced these adjustments, highlighting Ingram Micro Holding's addition to the Information Technology sector within the index.
Ingram Micro replaces Pacira BioSciences in S&P SmallCap 600 after Viatris acquisition.
Ingram Micro Holding Corp. is set to join the S&P SmallCap 600 index on November 17, 2026, replacing Pacira BioSciences. This change follows Viatris Inc.'s pending acquisition of Pacira BioSciences. The article also provides a market snapshot for Technology-sector US stocks, highlighting notable movers.
MSML ETF Profile: Dividends, Returns (AMEX:MSML)
The iShares MSCI USA Small-Cap ETF (MSML) provides exposure to US small-cap stocks, tracking the MSCI USA Small Cap Index. The fund, issued by BlackRock, Inc., has an AUM of $280.18 million, an expense ratio of 0.04%, and a dividend yield of 1.33%. It primarily invests in stocks, with significant exposure to the Finance and Health Technology sectors, and is predominantly focused on North America.
Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
Q32 Bio (Nasdaq: QTTB), a clinical-stage biotechnology company, announced its participation in a fireside chat at the 2026 Jefferies Global Healthcare Conference in London on November 18, 2026, at 12 p.m. GMT (7 a.m. ET). A webcast of the presentation will be available on the company's website, with an archived replay accessible for 90 days following the event. The company is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases.
Viatris to Participate in Upcoming Investor Conferences
Viatris (VTRS) announced its participation in three upcoming healthcare investor conferences: UBS (November 17, 2026), Jefferies (November 18, 2026), and Evercore (December 1, 2026). The company will engage in fireside chats, which retail investors can listen to live or via archived versions on investor.viatris.com. This announcement primarily informs shareholders about upcoming public speaking engagements by management, with no new financial results or business updates.
Viatris to Participate in Upcoming Investor Conferences
Viatris Inc. announced its participation in three upcoming healthcare conferences in November and December 2026. The global healthcare company will hold fireside chats at the UBS Global Biopharma Conference, the Jefferies Global Healthcare Conference, and the 9th Annual Evercore Healthcare Conference. Investors and the public can listen to these sessions live or access archived versions on the Viatris investor relations website.
What Pacira BioSciences Doubters Got Wrong
Pacira BioSciences saw a 49.2% return, including dividends, from the start of the year, despite skepticism. Bullish arguments in 2025 focused on CMS policy shifts, ambulatory surgery growth, and a Johnson & Johnson MedTech partnership, while bears highlighted reliance on EXPAREL and generic threats. The recent US$36.50 per share cash tender from Viatris, coupled with improved profitability on flatter revenue, suggests the optimists were more accurate.
Harrow Inc (HROW) Q3 2026 Earnings Call Highlights: Record Revenue of $99. ...
Harrow Inc. (HROW) reported record Q3 2026 revenue of $99.3 million, a 41% sequential and 39% year-over-year increase, driven largely by a 62% rise in branded revenue. VEVYE and TRIESENCE showed strong growth, and the company reaffirmed its full-year revenue guidance. However, full-year Adjusted EBITDA guidance was significantly lowered due to first-half shortfalls and lower gross margins, and a key clinical study for IHEEZO did not meet its primary endpoint.
Zymeworks lifts 2026 revenue guidance by about $59 million after $250 million Ziihera milestone
Zymeworks has significantly increased its 2026 revenue guidance by about $59 million to $337-351 million, alongside raising its adjusted EBITDA guidance. This surge was primarily driven by a $250 million milestone payment from Jazz Pharmaceuticals following FDA approval for Ziihera's first-line HER2-positive GEA, which also turned the third quarter profitable with net income reaching $173.7 million. The updated guidance assumes antitrust clearance for the ZW209 deal with Roche.
Harrow Q3 2026 Earnings Call Transcript
Harrow reported record third-quarter revenue of $99.3 million, a significant increase year-over-year, driven by strong performance from VEVYE, IHEEZO, and Triessence. The company reaffirmed its full-year revenue guidance of $350-$365 million, expecting a robust Q4 with contributions from newly acquired Tyrvaya. Harrow also updated its adjusted EBITDA outlook to over $40 million for the full year, reflecting strategic investments and accelerated R&D programs, and discussed the inconclusive primary endpoint of its Quell study but highlighted encouraging secondary and safety findings for IHEEZO.
Harrow earnings on deck as investors eye profitability return By Investing.com
Harrow Inc. is set to report third-quarter earnings, with investors keenly watching for a return to profitability after a disappointing second quarter. Analysts anticipate earnings of 20 cents per share on revenue of $99.1 million, a significant improvement driven by the acquisition of TYRVAYA and expanded sales efforts. The company's stock is trading near its 52-week low despite strong analyst buy ratings, making the upcoming report a crucial catalyst.
Health Care sector performance - S&P 500 health care stocks
The S&P 500 Health Care sector, comprising 59 companies worth $6.93 trillion, experienced a -0.15% decline on the day of November 6, 2026, despite a +19.5% year-to-date performance. Moderna Inc., Humana Inc., and Charles River Laboratories International Inc. were among the top gainers, while Insulet Corporation and DexCom Inc. were among the top losers. The article provides detailed performance metrics for each company within the sector, including daily, weekly, monthly, quarterly, year-to-date, and annual changes.